A Safety and Tolerability Study of Jaktinib

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

NCT02584777 ·Status: WITHDRAWN ·Phase: PHASE2

A Safety Study of XL019 in Adults With Myelofibrosis

NCT00522574 ·Status: TERMINATED ·Phase: PHASE1

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760 ·Status: RECRUITING ·Phase: PHASE2

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

NCT01773187 ·Status: TERMINATED ·Phase: PHASE3

Ruxolitinib in Patients With Myelofibrosis

NCT05762874 ·Status: UNKNOWN

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

NCT00745550 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

NCT00931762 ·Status: TERMINATED ·Phase: PHASE2

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

NCT01969838 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

NCT04878003 ·Status: RECRUITING ·Phase: PHASE2

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806 ·Status: RECRUITING ·Phase: PHASE2

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

NCT05044026 ·Status: COMPLETED

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

NCT06773195 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

NCT05447260 ·Status: UNKNOWN ·Phase: PHASE4

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

NCT03627403 ·Status: TERMINATED ·Phase: PHASE2

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

NCT00807677 ·Status: COMPLETED ·Phase: PHASE1

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

NCT01558739 ·Status: COMPLETED ·Phase: PHASE4

Momelotinib During and After HCT in Myelofibrosis

NCT07104799 ·Status: RECRUITING ·Phase: PHASE1

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

NCT05787496 ·Status: TERMINATED ·Phase: PHASE1

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

NCT02718300 ·Status: TERMINATED ·Phase: PHASE2

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

NCT02598297 ·Status: TERMINATED ·Phase: PHASE3

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

NCT02124746 ·Status: COMPLETED ·Phase: PHASE2